(Total Views: 279)
Posted On: 05/16/2017 5:53:25 AM
Post# of 22850
$IMGN,, more than double average volume yesterday and up $.09 in AH last night. NOTE: They did file a prospectus earlier in the month giving them the ability to raise up to $50m in stock sales.
http://archive.fast-edgar.com/20170511/AAZFL2...CLZDW7W292
Following are the Earnings Results posted on Friday:
ImmunoGen, Inc. (IMGN) Posts Quarterly Earnings Results, Beats Expectations By $0.16 EPS
Posted by Daniel Jordon on May 15th, 2017 // No Comments
ImmunoGen logoImmunoGen, Inc. (NASDAQ:IMGN) released its quarterly earnings results on Friday. The biotechnology company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.16. The company had revenue of $28.70 million during the quarter, compared to the consensus estimate of $16.16 million. The business’s revenue was up 45.7% on a year-over-year basis. During the same quarter last year, the firm earned ($0.37) EPS.
Shares of ImmunoGen (NASDAQ:IMGN) traded up 11.22% during trading on Monday, reaching $4.56. 5,422,220 shares of the company were exchanged. The firm’s 50 day moving average is $3.79 and its 200 day moving average is $2.74. The firm’s market capitalization is $407.43 million. ImmunoGen has a 1-year low of $1.51 and a 1-year high of $6.21.
Get ImmunoGen Inc. alerts:
Earnings History for ImmunoGen (NASDAQ:IMGN)
IMGN has been the topic of several recent analyst reports. Zacks Investment Research cut shares of ImmunoGen from a “hold” rating to a “sell” rating in a report on Tuesday, January 17th. Royal Bank of Canada set a $3.00 target price on shares of ImmunoGen and gave the company a “hold” rating in a report on Saturday, February 18th. Canaccord Genuity set a $6.00 target price on shares of ImmunoGen and gave the company a “buy” rating in a report on Saturday, February 18th. Morgan Stanley dropped their target price on shares of ImmunoGen from $2.50 to $1.30 and set an “underweight” rating on the stock in a report on Wednesday, March 1st. Finally, Cowen and Company restated a “hold” rating on shares of ImmunoGen in a report on Monday, March 13th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and three have given a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $4.53.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Redmile Group LLC bought a new position in ImmunoGen during the first quarter worth about $15,421,000. Bank of America Corp DE raised its position in shares of ImmunoGen by 10.5% in the first quarter. Bank of America Corp DE now owns 1,339,518 shares of the biotechnology company’s stock worth $5,183,000 after buying an additional 127,695 shares in the last quarter. Geode Capital Management LLC raised its position in shares of ImmunoGen by 3.5% in the first quarter. Geode Capital Management LLC now owns 678,343 shares of the biotechnology company’s stock worth $2,625,000 after buying an additional 22,991 shares in the last quarter. Vanguard Group Inc. raised its position in shares of ImmunoGen by 0.7% in the first quarter. Vanguard Group Inc. now owns 4,110,431 shares of the biotechnology company’s stock worth $15,907,000 after buying an additional 27,141 shares in the last quarter. Finally, Ngam Advisors L.P. raised its position in shares of ImmunoGen by 5.1% in the first quarter. Ngam Advisors L.P. now owns 300,599 shares of the biotechnology company’s stock worth $1,163,000 after buying an additional 14,629 shares in the last quarter. 85.26% of the stock is currently owned by institutional investors and hedge funds.
ImmunoGen Company Profile
ImmunoGen, Inc is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. The Company is engaged in the discovery of monoclonal antibody-based anticancer therapeutics. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target.
5 Day Chart for NASDAQ:IMGN
Receive News & Ratings for ImmunoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
http://archive.fast-edgar.com/20170511/AAZFL2...CLZDW7W292
Following are the Earnings Results posted on Friday:
ImmunoGen, Inc. (IMGN) Posts Quarterly Earnings Results, Beats Expectations By $0.16 EPS
Posted by Daniel Jordon on May 15th, 2017 // No Comments
ImmunoGen logoImmunoGen, Inc. (NASDAQ:IMGN) released its quarterly earnings results on Friday. The biotechnology company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.16. The company had revenue of $28.70 million during the quarter, compared to the consensus estimate of $16.16 million. The business’s revenue was up 45.7% on a year-over-year basis. During the same quarter last year, the firm earned ($0.37) EPS.
Shares of ImmunoGen (NASDAQ:IMGN) traded up 11.22% during trading on Monday, reaching $4.56. 5,422,220 shares of the company were exchanged. The firm’s 50 day moving average is $3.79 and its 200 day moving average is $2.74. The firm’s market capitalization is $407.43 million. ImmunoGen has a 1-year low of $1.51 and a 1-year high of $6.21.
Get ImmunoGen Inc. alerts:
Earnings History for ImmunoGen (NASDAQ:IMGN)
IMGN has been the topic of several recent analyst reports. Zacks Investment Research cut shares of ImmunoGen from a “hold” rating to a “sell” rating in a report on Tuesday, January 17th. Royal Bank of Canada set a $3.00 target price on shares of ImmunoGen and gave the company a “hold” rating in a report on Saturday, February 18th. Canaccord Genuity set a $6.00 target price on shares of ImmunoGen and gave the company a “buy” rating in a report on Saturday, February 18th. Morgan Stanley dropped their target price on shares of ImmunoGen from $2.50 to $1.30 and set an “underweight” rating on the stock in a report on Wednesday, March 1st. Finally, Cowen and Company restated a “hold” rating on shares of ImmunoGen in a report on Monday, March 13th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and three have given a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $4.53.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Redmile Group LLC bought a new position in ImmunoGen during the first quarter worth about $15,421,000. Bank of America Corp DE raised its position in shares of ImmunoGen by 10.5% in the first quarter. Bank of America Corp DE now owns 1,339,518 shares of the biotechnology company’s stock worth $5,183,000 after buying an additional 127,695 shares in the last quarter. Geode Capital Management LLC raised its position in shares of ImmunoGen by 3.5% in the first quarter. Geode Capital Management LLC now owns 678,343 shares of the biotechnology company’s stock worth $2,625,000 after buying an additional 22,991 shares in the last quarter. Vanguard Group Inc. raised its position in shares of ImmunoGen by 0.7% in the first quarter. Vanguard Group Inc. now owns 4,110,431 shares of the biotechnology company’s stock worth $15,907,000 after buying an additional 27,141 shares in the last quarter. Finally, Ngam Advisors L.P. raised its position in shares of ImmunoGen by 5.1% in the first quarter. Ngam Advisors L.P. now owns 300,599 shares of the biotechnology company’s stock worth $1,163,000 after buying an additional 14,629 shares in the last quarter. 85.26% of the stock is currently owned by institutional investors and hedge funds.
ImmunoGen Company Profile
ImmunoGen, Inc is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. The Company is engaged in the discovery of monoclonal antibody-based anticancer therapeutics. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target.
5 Day Chart for NASDAQ:IMGN
Receive News & Ratings for ImmunoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
(0)
(0)
'Everything works out in the end,,,If it hasn't worked out,,it's not the end'
https://twitter.com/twitter/statuses/957208055766241280
https://twitter.com/twitter/statuses/957208055766241280
Scroll down for more posts ▼
